The use of bromocriptine for the treatment of attention deficit disorder in two chemically dependent patients.
The dually diagnosed patient with attention deficit disorder, residual type (ADD-RT) may be especially prone to cocaine abuse, because ADD includes dopamine deficiencies and cocaine is a dopamine agonist. It is hypothesized that bromocriptine, a dopamine agonist, will reduce a patient's craving for cocaine and simultaneously address the patient's ADD-RT symptoms. A single-organism, double-blind research design is used to evaluate the efficacy of bromocriptine, as measured by scale 9 of the MMPI, the digit span and digit symbol tests of the Wechsler Intelligence Scale-Revised, and the signaling to numbers test. Statistical analysis of the results revealed an equivocal response to bromocriptine.
Cavanagh
R
R
New Mexico State University, Las Cruces.
Clifford
J S
JS
Gregory
W L
WL
D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D001971:Bromocriptine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008950:MMPI; D008297:Male; D011897:Random Allocation; D019966:Substance-Related Disorders / Q000150:complications* / Q000523:psychology
D001971:Bromocriptine